From GlobeNewswire:

Oculis Holding AG is hosting an in-person R&D Day in New York City on Feb 28, 2024 to discuss their clinical programs. OCS-01 aims to provide an early intervention for Diabetic Macular Edema, while OCS-02 plans to treat Dry Eye Disease. Both products are part of Oculis’ innovative pipeline.

Speakers presenting at the event include prominent figures in the ophthalmology field such as doctors from the University of Southern California, University of Nevada, and the University of Miami among others. The event will also include a review of Oculis’ performance and outlook for 2024.

Oculis is a Switzerland based biopharmaceutical company with a goal to improve eye care and save sight. Its pipeline includes potential treatments for DME, Dry Eye Disease, and acute optic neuritis. The company’s management team is experienced and has a successful track record. For more information, visit www.oculis.com.



Read more: Oculis to Host In-Person & Virtual R&D Day in New York on